Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems

AAPS Journal

Volumn 13, Issue 4, 2011, Pages 632-649

  Martinez, Marilyn N ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

animal model; interspecies differences; parenteral drug delivery; pharmacokinetics

Indexed keywords

1 METHYL 2 PYRROLIDINONE; ALENDRONIC ACID; AMPHOTERICIN B; AMPICILLIN; CEFOXITIN; CONTRAST MEDIUM; DIDANOSINE; GLYCOPROTEIN P; GLYCOSAMINOGLYCAN; HALOFANTRINE; HERMES ANTIGEN; HYALURONIC ACID; HYALURONIDASE; INSULIN; INSULIN ASPART; IVERMECTIN; LIPOPROTEIN; LIPOSOME; MICROSPHERE; NANOPARTICLE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; NYSTATIN; PLASMA PROTEIN; PROPAFENONE; RECOMBINANT ERYTHROPOIETIN;

ACTIVE TRANSPORT; ANALYTICAL PARAMETERS; ANAPHYLAXIS; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BIOCOMPATIBILITY; BIOLOGICAL MODEL; BLOOD BRAIN BARRIER; CANCER RESEARCH; CENTRAL NERVOUS SYSTEM; CHEMICAL COMPOSITION; COMPLEMENT SYSTEM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG TRANSPORT; EXCIPIENT COMPATIBILITY; EXPERIMENTAL ANIMAL; GENETIC VARIABILITY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IMMUNE RESPONSE; IMMUNOGENICITY; INFLAMMATION; INTERSTITIUM; INTESTINE MUCOSA; LIPID COMPOSITION; LIPOPHILICITY; LYMPHATIC SYSTEM; MICROENCAPSULATION; NONHUMAN; ORGAN BLOOD FLOW; OSMOTIC PRESSURE; PARENTERAL DRUG ADMINISTRATION; PASSIVE TRANSPORT; PHYSIOLOGICAL PROCESS; PLASMA PROTEIN BINDING; PREDICTIVE VALUE; SEQUENCE HOMOLOGY; SOMATIC GENE THERAPY; SPECIES DIFFERENCE; STEREOSPECIFICITY; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE FLUID VOLUME;

ANIMALS; DRUG DELIVERY SYSTEMS; INFUSIONS, PARENTERAL; MODELS, ANIMAL;

EID: 83555173607     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-011-9303-8     Document Type: Article

References (109)

1. Martinez M. Interspecies differences in physiology and pharmacology: extrapolating preclinical data to human populations. In: Rogge MC, Taft DR, editors. Preclinical Drug Development. 2nd ed. Boca Raton: Taylor and Francis Group; 2009. p. 35-70.
2. TT Kararli 1995 Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals Biopharm Drug Dispos 16 5 351 380 8527686 1:CAS:528:DyaK2MXmvFOls70%3D 10.1002/bdd.2510160502
3. de Zwart LL, Rompelberg CJM, Sips AJAM, Welink J, and van Engelen JGM. Anatomical and physiological differences between various species used in studies on the pharmacokinetics and toxicology of xenobiotics. A review of literature. RIVM report 623860 010: October 1999. http://www.rivm.nl/bibliotheek/rapporten/ 623860010.pdf. Accessed 1 Oct 2011.
4. M Martignoni GMM Groothuis R de Kanter 2006 Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition, and induction Expert Opin Drug Metab Toxicol 2 6 875 894 17125407 1:CAS:528:DC%2BD28Xht1eks7nJ 10.1517/17425255.2.6.875 (Pubitemid 44911538)
5. MN Martinez WM Pedersoli WR Ravis JD Jackson R Cullison 2001 Feasibility of interspecies extrapolation in determining the bioequivalence of animal products intended for intramuscular administration J Vet Pharmacol Ther 24 2 125 135 11442787 1:CAS:528:DC%2BD3MXlslOgtb0%3D 10.1046/j.1365-2885.2001.00316.x (Pubitemid 32631429)
6. A Lifschitz A Pis L Alvarez G Virkel S Sanchez J Sallovitz, et al. 1999 Bioequivalence of ivermectin formulations in pigs and cattle J Vet Pharmacol Ther 22 1 27 34 10211714 1:CAS:528:DyaK1MXisVKmsL4%3D 10.1046/j.1365-2885.1999. 00172.x (Pubitemid 29132273)
7. K Hirano H Yamada 1982 Studies on the absorption of practically water-insoluble drugs following injection VI: subcutaneous absorption from aqueous suspensions in rats J Pharm Sci 71 5 500 505 7097492 1:CAS:528:DyaL38XktFKmu7w%3D 10.1002/jps.2600710506 (Pubitemid 12063721)
8. C Larsen SW Larsen H Jensen A Yaghmur J Ostergaard 2009 Role of in vitro release models in formulation development and quality control of parenteral depots Expert Opin Drug Deliv 6 12 1283 1295 19941410 1:CAS:528: DC%2BD1MXhs1aqtLfF 10.1517/17425240903307431
9. H Wiig RK Reed O Tenstad 2000 Interstitial fluid pressure, composition of interstitium, and interstitial exclusion of albumin in hypothyroid rats Am J Physiol Heart Circ Physiol 278 5 H1627 H1639 10775143 1:CAS:528: DC%2BD3cXjvFahsL4%3D
10. H Schriftman AA Kondritzer 1957 Absorption of atropine from muscle Am J Physiol 191 3 591 594 13487786 1:CAS:528:DyaG1cXjtFCkug%3D%3D
11. EA Saikawa M Masegi M Hashida H Sezaki 1992 Contribution of interstitial diffusion in drug absorption from perfused rabbit muscle: effect of hyaluronidase on absorption Chem Pharm Bull (Tokyo) 40 3 737 740
12. AL Dunn JE Heavner G Racz M Day 2010 Hyaluronidase: a review of approved formulations, indications and off-label use in chronic pain management Expert Opin Biol Ther 10 1 127 131 20420518 1:CAS:528:DC%2BD1MXhsFChsLjL 10.1517/14712590903490382
13. MS Hanhn JB Kobler BC Starcher SM Zeitels R Langer 2006 Quantitative and comparative studies of the vocal fold extracellular matrix. I: elastic fibers and hyaluronic acid Ann Otol Rhinol Laryngol 115 2 156 164
14. UB Laurent KA Granath 1983 The molecular weight of hyaluronate in the aqueous humour and vitreous body of rabbit and cattle eyes Exp Eye Res 36 4 481 492 6852129 1:CAS:528:DyaL3sXitFWrs7s%3D 10.1016/0014-4835(83)90042-8 (Pubitemid 13125032)
15. Kuo JW. Practical aspects of hyaluronoan-based medical products. New York: CRC Press; 2006.
16. R Stern AA Asari KN Sugahara 2006 Hyaluronan fragments: an information-rich system Eur J Cell Biol 85 8 699 715 16822580 1:CAS:528:DC%2BD28XptlSnt7c%3D 10.1016/j.ejcb.2006.05.009 (Pubitemid 44070579)
17. BP Toole 2004 Hyaluronan: from extracellular glue to pericellular cue Nat Rev Cancer 4 7 528 539 15229478 1:CAS:528:DC%2BD2cXlt1OktrY%3D 10.1038/nrc1391 (Pubitemid 38868622)
18. BP Toole MG Slomiany 2008 Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells Semin Cancer Biol 18 4 244 250 18534864 1:CAS:528:DC%2BD1cXntlGhtrk%3D 10.1016/j.semcancer.2008.03.009
19. P Johnson B Ruffell 2009 CD44 and its role in inflammation and inflammatory diseases Inflamm Allergy Drug Targets 8 3 208 220 19601881 1:CAS:528:DC%2BD1MXoslCju7s%3D
20. K Gee M Kryworuchko A Kumar 2004 Recent advances in the regulation of CD44 expression and its role in inflammation and autoimmune diseases Arch Immunol Ther Exp (Warsz) 52 1 13 26 1:CAS:528:DC%2BD2cXktl2ktbo%3D (Pubitemid 39317967)
21. VM Platt FC Szoka Jr 2008 Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor Mol Pharm 5 4 474 486 18547053 1:CAS:528:DC%2BD1cXmvFOktbg%3D 10.1021/mp800024g
22. EJ Oh K Park KS Kim J Kim JA Yang JH Kong, et al. 2010 Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives J Control Release 141 1 2 12 19758573 1:CAS:528:DC%2BD1MXhsFWls7zI 10.1016/j.jconrel.2009.09.010
23. RE Eliaz FC Szoka Jr 2001 Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells Cancer Res 61 6 2592 2601 11289136 1:CAS:528:DC%2BD3MXisVSks7s%3D (Pubitemid 32685844)
24. BT Bosworth T St John WM Gallatin JA Harp 1991 Sequence of the bovine CD44 cDNA: comparison with human and mouse sequences Mol Immunol 28 10 1131 1135 1922105 1:CAS:528:DyaK3sXhslagsw%3D%3D 10.1016/0161-5890(91)90028-I
25. S Nedvetzki I Golan N Assayag E Gonen D Caspi M Gladnikoff, et al. 2003 A mutation in a CD44 variant of inflammatory cells enhances the mitogenic interaction of FGF with its receptor J Clin Invest 111 8 1211 1220 12697740 1:CAS:528:DC%2BD3sXjtFCrs7s%3D (Pubitemid 36519938)
26. RI Skotheim M Nees 2007 Alternative splicing in cancer: noise, functional, or systematic? Int J Biochem Cell Biol 39 7-8 1432 1449 17416541 1:CAS:528:DC%2BD2sXnslWltbw%3D 10.1016/j.biocel.2007.02.016 (Pubitemid 47031033)
27. KF Milde R Alejandro RL Pastori 1994 Expression of CD44 variant transcripts in dog lymphatic tissue Immunogenetics 40 6 437 444 7525471 1:CAS:528:DyaK2MXislOlu7k%3D 10.1007/BF00177826 (Pubitemid 24330200)
28. Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J. 2011. doi: 10.1111/j.1742-4658.2011.08071.x.
29. PD Watson 1998 Analysis of the paired-tracer method of determining cell uptake Am J Physiol 275 2 Pt 1 E366 E371 9688641 1:CAS:528:DyaK1cXlsVCkt7g%3D
30. UM Hollenstein M Brunner R Schmid M Müller 2001 Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing Int J Obes Relat Metab Disord 25 3 354 358 11319632 1:CAS:528:DC%2BD3MXisFyns74%3D 10.1038/sj.ijo.0801555 (Pubitemid 32209810)
31. G Schmittmann UD Rohr 2000 Comparison of the permeability surface product (PS) of the blood capillary wall in skeletal muscle tissue of various species and in vitro porous membranes using hydrophilic drugs J Pharm Sci 89 1 115 127 10664544 1:CAS:528:DC%2BD3cXit1eisLY%3D 10.1002/(SICI)1520-6017(200001)89: 1<115::AID-JPS12>3.0.CO;2-7 (Pubitemid 30080160)
32. CJ Porter GA Edwards SA Charman 2001 Lymphatic transport of proteins after s.c. injection: implications of animal model selection Adv Drug Deliv Rev 50 1-2 157 171 11489338 1:CAS:528:DC%2BD3MXlsF2jsL4%3D 10.1016/S0169-409X(01) 00153-3 (Pubitemid 32727281)
33. GA Edwards CJ Porter SM Caliph SM Khoo WN Charman 2001 Animal models for the study of intestinal lymphatic drug transport Adv Drug Deliv Rev 50 1-2 45 60 11489333 1:CAS:528:DC%2BD3MXlsF2js7s%3D 10.1016/S0169-409X(01)00148-X (Pubitemid 32727276)
34. L Kagan P Gershkovich A Mendelman S Amsili N Ezov A Hoffman 2007 The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model Eur J Pharm Biopharm 67 3 759 765 17499981 1:CAS:528:DC%2BD2sXhtF2qsLvJ 10.1016/j.ejpb.2007.04.002 (Pubitemid 47576609)
35. C Oussoren J Zuidema DJA Crommelin G Storm 1997 Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. I. Influence of the anatomical site of injection J Liposome Res 7 1 85 99 10.3109/08982109709035487
36. C Oussoren G Storm 2001 Liposomes to target the lymphatics by subcutaneous administration Adv Drug Deliv Rev 50 1-2 143 156 11489337 1:CAS:528:DC%2BD3MXlsF2js7c%3D 10.1016/S0169-409X(01)00154-5 (Pubitemid 32727280)
37. J Kota KK Machavaram DN McLennan GA Edwards CJ Porter SA Charman 2007 Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepoetin alfa using a sheep model Drug Metab Dispos 35 12 2211 2217 17875672 1:CAS:528:DC%2BD2sXhsVeiurzF 10.1124/dmd.107.015669 (Pubitemid 350146207)
38. H Bleuel R Hoffmann B Kaufmann P Neubert PP Ochlich W Schaumann 1996 Kinetics of subcutaneous versus intravenous epoetin-beta in dogs, rats and mice Pharmacology 52 5 329 338 8807677 1:CAS:528:DyaK28XjvVGlsbg%3D 10.1159/000139398 (Pubitemid 26162792)
39. S Woo WJ Jusko 2007 Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin Drug Metab Dispos 35 9 1672 1678 17576810 1:CAS:528:DC%2BD2sXpslKqsL8%3D 10.1124/dmd.107.015248 (Pubitemid 47296063)
40. A Caldini G Moneti A Fanelli A Bruschettini S Mercurio G Pieraccini, et al. 2003 Epoetin alpha, epoetin beta and darbepoetin alfa: two-dimensional gel electrophoresis isoforms characterization and massspectrometry analysis Proteomics 3 6 937 941 12833517 1:CAS:528:DC%2BD3sXltlSmu74%3D 10.1002/pmic.200300405 (Pubitemid 36801680)
41. DN McLennan CJH Porter GA Edwards SW Martin AC Heatherington SA Charman 2005 Lymphatic absorption is the primary contributor to the systemic availability of epoetin alfa following subcutaneous administration to sheep J Pharmacol Exp Ther 313 1 345 351 15579493 1:CAS:528:DC%2BD2MXjtlSntr0%3D 10.1124/jpet.104.078790 (Pubitemid 40411360)
42. A Plum H Agerso L Andersen 2000 Pharmacokinetics of the rapid-acting insulin analog, insulin aspart, in rats, dogs, and pigs, and pharmacodynamics of insulin aspart in pigs Drug Metab Dispos 28 2 155 160 10640512 1:CAS:528:DC%2BD3cXot1Witw%3D%3D (Pubitemid 30068998)
43. B Davies T Morris 1993 Physiological parameters in laboratory animals and humans Pharm Res 10 7 1093 1095 8378254 1:STN:280:DyaK3szptFaqsg%3D%3D 10.1023/A:1018943613122 (Pubitemid 23211439)
44. DR Brocks M Ramaswamy AI MacInnes KM Wasan 2000 The stereoselective distribution of halofantrine enantiomers within human, dog, and rat plasma lipoproteins Pharm Res 17 4 427 431 10870986 1:CAS:528:DC%2BD3cXktFalsbk%3D 10.1023/A:1007524919865 (Pubitemid 30395297)
45. T Kosa T Maruyama N Sakai N Yonemura S Yahara M Otagiri 1998 Species differences of serum albumins: I: drug binding sites Pharm Res 14 11 1607 1612 10.1023/A:1012138604016
46. A Fura TW Harper H Zhang L Fung WC Shyu 2003 Shift in pH of biological fluids during storage and processing: effect on bioanalysis J Pharm Biomed Anal 32 3 513 522 14565556 1:CAS:528:DC%2BD3sXntVWksbo%3D 10.1016/S0731-7085(03) 00159-6 (Pubitemid 38021842)
47. CJ Kochansky DR McMasters P Lu KA Koeplinger HH Kerr M Shou, et al. 2008 Impact of pH on plasma protein binding in equilibrium dialysis Mol Pharm 5 3 438 448 18345638 1:CAS:528:DC%2BD1cXjsVWhurw%3D 10.1021/mp800004s (Pubitemid 351929828)
48. M Pistolozzi C Bertucci 2008 Species-dependent stereoselective drug binding to albumin: a circular dichronism study Chirality 20 3-4 552 558 18172833 1:CAS:528:DC%2BD1cXis12hu7c%3D 10.1002/chir.20521 (Pubitemid 351303995)
49. P Kurtzhals S Havelund I Jonassen B Kiehr U Ribel J Markussen 1996 Albumin binding and time action of acylated insulins in various species J Pharm Sci 85 3 304 308 8699334 1:CAS:528:DyaK28XpsFKjsA%3D%3D 10.1021/js950412j (Pubitemid 26082476)
50. NE Basken CJ Mathias AE Lipka MA Green 2008 Species dependence of [64Cu]Cu-Bis(thiosemicarbazone) radiopharmaceutical binding to serum albumins Nucl Med Biol 35 3 281 286 18355683 1:CAS:528:DC%2BD1cXjs1Kit7k%3D 10.1016/j.nucmedbio.2007.11.009
51. MC Giron 2009 Radiopharmaceutical pharmacokinetics in animals: critical considerations Q J Nucl Med Mol Imaging 53 4 359 364 19834444 1:STN:280:DC%2BD1MnpsFKgtQ%3D%3D
52. A Puigdemont M Arboix F Gaspari A Bortolotti M Bonati 1989 In-vitro plasma protein binding of propafenone and protein profile in eight mammalian species Res Commun Chem Pathol Pharmacol 64 3 435 440 2781140 1:CAS:528:DyaL1MXkslShurg%3D (Pubitemid 19169540)
53. JH Lin IW Chen FA Deluna 1994 Nonlinear kinetics of aldronate. Plasma protein binding and bone uptake Drug Metab Disp 22 3 400 405 1:CAS:528:DyaK2cXkt1Khsr0%3D (Pubitemid 24158538)
54. Bonapace CR, Fowler S, Laessig KA, Lazor JA, Nambiar S. Ceftriaxone and calcium-containing fluids-rationale for product label changes, abstr. A1-008. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. Washington: American Society for Microbiology; 2009.
55. KM Wasan DR Brocks SD Lee K Sachs-Barrable SJ Thornton 2008 Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery Nat Rev Drug Discov 7 1 84 99 18079757 1:CAS:528:DC%2BD1cXht1ygtA%3D%3D 10.1038/nrd2353
56. M Ramaswamy TL Wallace PA Cossum KM Wasan 1999 Species differences in the proportion of plasma lipoprotein lipid carried by high-density lipoproteins influence the distribution of free and liposomal nystatin in human, dog, and rat plasma Antimicrob Agents Chemother 43 6 1424 1428 10348764 1:CAS:528: DyaK1MXjs12nsLY%3D (Pubitemid 29259337)
57. I Bekersky RM Fielding DE Dressler JW Lee DN Buell TJ Walsh 2002 Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans Antimicrob Agents Chemother 46 3 828 833 11850268 1:CAS:528:DC%2BD38XhsVKhuro%3D 10.1128/AAC.46.3.828-833. 2002 (Pubitemid 34157670)
58. Y Hong PJ Shaw BN Tattam CE Nath JW Earl KR Stephen, et al. 2007 Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases Eur J Clin Pharmacol 63 2 165 172 17180621 1:CAS:528:DC%2BD2sXnsFykug%3D%3D 10.1007/s00228-006-0240-x (Pubitemid 46147058)
59. Y Jin P Ai R Xin Y Tian J Dong D Chen, et al. 2009 Self-assembled drug delivery systems: Part 3. In vitro/in vivo studies of the self-assembled nanoparticulates of cholesteryl acyl didanosine Int J Pharm 368 1-2 207 214 19007871 1:CAS:528:DC%2BD1MXhsFertL0%3D 10.1016/j.ijpharm.2008.10.009
60. M Jemal DJ Hawthorne 1997 Quantitative determination of BMS-186716, a thiol compound, in rat plasma by high-performance liquid chromatography-positive ion electrospray mass spectrometry after hydrolysis of the methyl acrylate adduct by the native esterases J Chromatogr B: Biomed Sci Appl 698 1-2 123 132 1:CAS:528:DyaK2sXlslemsrY%3D 10.1016/S0378-4347(97)00292-2 (Pubitemid 27412513)
61. T Minagawa Y Kohno T Suwa A Tsuji 1995 Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases Biochem Pharmacol 49 10 1361 1365 7763277 1:CAS:528:DyaK2MXlvFSitb0%3D 10.1016/0006-2952(95)00071- 7
62. MA Dobrovolskaia P Aggarwal JB Hall SE McNeil 2008 Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution Mol Pharm 5 4 487 495 18510338 1:CAS:528:DC%2BD1cXmsVOhuro%3D 10.1021/mp800032f
63. PJ Haley 2003 Species differences in the structure and function of the immune system Toxicology 188 1 49 71 12748041 1:CAS:528:DC%2BD3sXjs1ahs7g%3D 10.1016/S0300-483X(03)00043-X (Pubitemid 36577153)
64. V Brinks W Jiskoot H Schellekens 2011 Immunogenicity of therapeutic proteins: the use of animal models Pharm Res 28 10 2379 2385 21744171 1:CAS:528:DC%2BC3MXos1Onu7Y%3D 10.1007/s11095-011-0523-5
65. T Ishida H Harashima H Kiwada 2001 Interactions of liposomes with cells in vitro and in vivo: opsonins and receptors Curr Drug Metab 2 4 397 409 11766990 1:CAS:528:DC%2BD3MXptVeitL4%3D 10.2174/1389200013338306 (Pubitemid 33133983)
66. DE Owens NA Peppas 2006 Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int J Pharm 307 1 93 102 16303268 1:CAS:528:DC%2BD2MXht12isrvM 10.1016/j.ijpharm.2005.10.010 (Pubitemid 41773257)
67. SM Moghimi AC Hunter 2001 Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups Pharm Res 18 1 1 8 11336343 1:CAS:528:DC%2BD3MXjtFajsbc%3D 10.1023/A:1011054123304 (Pubitemid 32299615)
68. X Yan GL Scherphof JA Kamps 2005 Liposome opsonization J Liposome Res 15 1-2 109 139 16194930 1:CAS:528:DC%2BD2MXmtlWiuro%3D (Pubitemid 40976309)
69. D Liu Q Hu YK Song Song 1995 Liposome clearance from blood: different animal species have different mechanisms Biochemica et Biophysica Acta 1240 2 277 284 10.1016/0005-2736(95)00184-0 (Pubitemid 26004752)
70. TM Huong H Harashima H Kiwada 1999 In vivo studies on the role of complement in the clearance of liposomes in rats and guinea pigs Biol Pharm Bull 22 5 515 520 10375174 1:CAS:528:DyaK1MXjsFShurg%3D 10.1248/bpb.22.515 (Pubitemid 29252227)
71. A Kurihara Y Shibayama A Kasuya M Ikeda M Hisaoka 1998 Species variation in pharmacokinetics and opsonization of palmitoyl rhizoxin (RS-1541) incorporated in lipid emulsions J Drug Target 5 6 491 505 9783680 1:CAS:528:DyaK1cXntF2ltr8%3D 10.3109/10611869808997875 (Pubitemid 28499683)
72. J Szebeni 2005 Complement activation-related pseudoallergy caused by amphiphilic drug carriers: the role of lipoproteins Curr Drug Deliv 2 4 443 449 16305447 1:CAS:528:DC%2BD2MXhtVSkt7zE 10.2174/156720105774370212 (Pubitemid 41277776)
73. J Szebeni CR Alving L Rosivall R Bünger L Baranyi P Bedöcs, et al. 2007 Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles J Liposome Res 17 2 107 117 17613700 1:CAS:528:DC%2BD2sXnt1WisrY%3D 10.1080/08982100701375118 (Pubitemid 47026981)
74. S Liu T Ishida H Kiwada 1997 Effect of serum components from different species on destabilizing hydrogenated phosphatidylcholine-based liposomes Biol Pharm Bull 20 8 874 880 9300134 1:CAS:528:DyaK2sXlslyktb8%3D 10.1248/bpb.20.874 (Pubitemid 27382754)
75. H Harashima S Komatsu S Kojima C Yanagi Y Morioka M Naito, et al. 1996 Species difference in the disposition of liposomes among mice, rats, and rabbits: allometric relationship and species dependent hepatic uptake mechanism Pharm Res 13 7 1049 1054 8842043 1:STN:280:DyaK28vjvFOhuw%3D%3D 10.1023/A:1016058724452 (Pubitemid 26259005)
76. C Matschkea U Iselea P van Hoogevestb A Fahrc 2002 Sustained-release injectables formed in situ and their potential use for veterinary products J Control Release 85 103 1 15 10.1016/S0168-3659(02)00266-3 (Pubitemid 35449450)
77. CB Packhaeuser J Schnieders CG Oster T Kissel 2004 In situ forming parenteral drug delivery systems: an overview Eur J Pharm Biopharm 58 2 445 455 15296966 1:CAS:528:DC%2BD2cXmsVGnsL0%3D 10.1016/j.ejpb.2004.03.003 (Pubitemid 39037247)
78. PS Leppert L Cammack R Cargill L Coffman M Cortese K Engle, et al. 1994 Interspecies differences in systemic drug availability following subcutaneous pulsatile administration in cattle, sheep, dogs, and rats J Biomed Mater Res 28 6 713 722 8071382 1:CAS:528:DyaK2cXkvFWntL8%3D 10.1002/jbm.820280608 (Pubitemid 24148321)
79. MJ Ali Y Navalitloha MW Vavra EW Kang AC Itskovich P Molnar, et al. 2006 Isolation of drug delivery from drug effect: problems of optimizing drug delivery parameters Neuro Oncol 8 2 109 118 16533759 1:CAS:528: DC%2BD28XksFSrtbs%3D 10.1215/15228517-2005-007 (Pubitemid 46542655)
80. RK Jain 1987 Transport of molecules in the tumor interstitium: a review Cancer Res 47 12 3039 3051 3555767 1:CAS:528:DyaL2sXksFKlu7Y%3D (Pubitemid 17082621)
81. PA Netti LM Hamberg JW Babich D Kierstead W Graham GJ Hunter, et al. 1999 Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules Proc Natl Acad Sci U S A 96 6 3137 3142 10077650 1:CAS:528:DyaK1MXhvFykt7k%3D 10.1073/pnas.96.6.3137 (Pubitemid 29148857)
82. M Stohrer Y Boucher M Stangassinger RK Jain 2000 Oncotic pressure in solid tumors is elevated Cancer Res 60 15 4251 4255 10945638 1:CAS:528:DC%2BD3cXlvFOktb4%3D (Pubitemid 30636613)
83. LA Thomas SA Brown 1992 Relationship between colloid osmotic pressure and plasma protein concentration in cattle, horses, dogs, and cats Am J Vet Res 53 12 2241 2244 1282310 1:CAS:528:DyaK3sXls12qsA%3D%3D
84. BW Zweifach M Intaglietta 1971 Measurement of blood plasma colloid osmotic pressure: II. Comparative study of different species Microvasc Res 3 1 83 88 10.1016/0026-2862(71)90009-4
85. PD Navar LG Navar 1977 Relationship between colloid osmotic pressure and plasma protein concentration in the dog Am J Physiol 233 2 H295 H298 888972 1:CAS:528:DyaE2sXltlWguro%3D
86. RP Brown MD Delp SL Lindstedt LR Rhomberg RP Beliles 1997 Physiological parameter values for physiologically based pharmacokinetic models Toxicol Ind Health 13 4 407 484 9249929 1:CAS:528:DyaK2sXltl2itrk%3D (Pubitemid 27314117)
87. Chang PL. Non-autologous somatic gene therapy. In: Chang PL, editor. Somatic gene therapy. Boca Raton: CRC Press, Inc; 1995. p. 203-24.
88. CJD Ross M Ralph PL Chang 2000 Somatic gene therapy for a neurodegenerative disease using microencapsulated recombinant cells Exp Neurol 166 2 276 286 11085893 1:CAS:528:DC%2BD3cXotFCrsbg%3D 10.1006/exnr.2000.7531
89. C Gagliardi BA Bunnell 2009 Large animal models of neurological disorders for gene therapy ILAR J 50 2 128 143 19293458 1:CAS:528:DC%2BD1MXps1eksbo%3D
90. SC Barsoum W Milgram W Mackay C Coblentz KH Delaney JM Kwiecien, et al. 2003 Delivery of recombinant gene product to canine brain with the use of microencapsulation J Lab Clin Med 142 6 399 413 14713892 1:CAS:528: DC%2BD3sXhtVShs7zO 10.1016/j.lab.2003.07.002 (Pubitemid 38102024)
91. R Shull X Lu I Dube C Lutzko S Kruth A Abrams-Oqq, et al. 1996 Humoral immune response limits gene therapy in canine MPS I Blood 88 1 377 379 8704199 1:CAS:528:DyaK28XjvFSntLk%3D (Pubitemid 26235246)
92. RM Shull X Lu MF McEntee RM Bright KA Pepper DB Kohn 1996 Myoblast gene therapy in canine mucopolysaccharidosis. I. Abrogation by an immune response to alpha-L-iduronidase Hum Gene Ther 7 13 1595 1603 8864760 1:CAS:528: DyaK28Xls1GmsL4%3D 10.1089/hum.1996.7.13-1595 (Pubitemid 26302214)
93. P Aebischer M Goddard AP Signore RL Timpson 1994 Functional recovery in hemiparkinsonian primates transplanted with polymer-encapsulated PC12 cells Exp Neurol 126 2 151 158 7925816 1:CAS:528:DyaK2cXlslSgsbc%3D 10.1006/exnr.1994.1053 (Pubitemid 24182036)
94. P Aebischer M Schluep N Déglon JM Joseph L Hirt B Heyd, et al. 1996 Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients Nat Med 2 6 696 699 8640564 1:CAS:528:DyaK28XjsVSjur8%3D 10.1038/nm0696-696 (Pubitemid 26191960)
95. J Bloch AC Bachoud-Lévi N Déglon JP Lefaucheur L Winkel S Palfi, et al. 2004 Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study Hum Gene Ther 15 10 968 975 15585112 1:CAS:528:DC%2BD2cXot1OitL0%3D 10.1089/hum.2004.15.968 (Pubitemid 39372573)
96. J Kawakami K Yamamoto Y Sawada T Iga 1994 Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data J Pharmacokinet Biopharm 22 3 207 227 7884650 1:CAS:528:DyaK2MXjsVams7Y%3D 10.1007/BF02353329 (Pubitemid 24378180)
97. Smith EK, Gustafson EL, Borden LA, Dhar TGM, Durkin MM, Vaysse PJJ, et al. Heterogeneity of brain GABA transporters. In: Tanaka C, Bowery NG, editors. GABA: receptors, transporters, and metabolism. Switzerland: Birkauser Verlag; 1996. p. 63-72.
98. NA Sharif JL Nunes AD Michel RL Whiting 1989 Comparative properties of the dopamine transport complex in dog and rodent brain: striatal [(3)H]GBR12935 binding and [(3)H]dopamine uptake Neurochem Int 15 3 325 332 20504502 1:CAS:528:DyaK3cXntVKjtw%3D%3D 10.1016/0197-0186(89)90140-X (Pubitemid 19279830)
99. DZ Gerhart RL Leino ND Borson WE Taylor KM Gronlund AL McCall, et al. 1995 Localization of glucose transporter GLUT 3 in brain: comparison of rodent and dog using species-specific carboxyl-terminal antisera Neuroscience 66 1 237 246 7637872 1:CAS:528:DyaK2MXls1Sht74%3D 10.1016/0306-4522(94)00544-F
100. GJ Mantych DE James HD Chung SU Devaskar 1992 Cellular localization and characterization of Glut 3 glucose transporter isoform in human brain Endocrinology 131 3 1270 1278 1505464 1:CAS:528:DyaK38XlvVyktb0%3D 10.1210/en.131.3.1270
101. Westerhout J, Danhof M, De Lange EC. Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. J Pharm Sci. 2011. doi: 10.1002/jps.
102. MS Warren N Zerangue K Woodford LM Roberts EH Tate B Feng, et al. 2009 Comparative gene expression profiles of ABC transporters in brain microvessel, endothelial cells and brain in five species including human Pharmacol Res 59 6 404 413 19429473 1:CAS:528:DC%2BD1MXltFemu7g%3D 10.1016/j.phrs.2009.02.007
103. S Baltes AM Gastens M Fedrowitz H Potschka V Kaever W Löscher 2007 Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein Neuropharmacology 52 2 333 346 17045309 1:CAS:528:DC%2BD2sXhtVCqu74%3D 10.1016/j.neuropharm.2006.07.038 (Pubitemid 46123353)
104. S Syvänen O Lindhe M Palner BR Kornum O Rahman B Långström, et al. 2009 Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport Drug Metab Dispos 37 3 635 643 19047468 10.1124/dmd.108.024745 1:CAS:528:DC%2BD1MXislamtbo%3D
105. X Liu C Chen BJ Smith 2008 Progress in brain penetration evaluation in drug discovery and development J Pharm Exp Ther 325 2 349 356 1:CAS:528:DC%2BD1cXlsVOjsL0%3D 10.1124/jpet.107.130294 (Pubitemid 351574780)
106. H Reiber P Thiele 1983 Species-dependent variables in blood cerebrospinal fluid barrier function for proteins J Clin Chem Clin Biochem 21 4 199 202 6854231 1:CAS:528:DyaL3sXhvFGlu7w%3D (Pubitemid 13120132)
107. SV Dhuria LR Hanson WH Frey 2nd 2010 Intranasal delivery to the central nervous system: mechanisms and experimental considerations J Pharm Sci 99 4 1654 1673 19877171 1:CAS:528:DC%2BC3cXht12gs7Y%3D
108. CH Liu Z You JQ Ren YR Kim K Eikermann-Haerter PK Liu 2008 Noninvasive delivery of gene targeting probes to live brains for transcription MRI FASEB J 22 4 1193 1203 18029447 1:CAS:528:DC%2BD1cXktlWntrs%3D 10.1096/fj.07-9557com (Pubitemid 351519973)
109. L Di JP Umland G Chang Y Huang Z Lin DO Scott, et al. 2011 Species independence in brain tissue binding using brain homogenates Drug Metab Dispos 39 7 1270 1277 21474681 1:CAS:528:DC%2BC3MXosFWktrg%3D 10.1124/dmd.111.038778